The Effectiveness of Epidermal Growth Factor Serum in Improve Facial Skin Hydration, Elasticity, Pigmentation, and Wrinkles.

NCT05724589 | Completed Results

• 1 other identifier: 008/2565
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

EGF is a polypeptide that promotes cell differentiation and collagen production while decreasing melanin production. This study is designed to study its effectiveness in improving the texture and appearance of facial skin after daily topical application. We hypothesized that EGF would improve facial skin hydration, elasticity, pigmentation, and wrinkles.

Conditions

Aging

Outcome Measures

Primary Outcomes (6)

• Facial Skin Hydration

  Facial skin hydration was measured using a Corneometer, which provides readings in arbitrary units (a.u.). Measurements were taken at baseline (Day 0), Week 8, Week 12, and Week 16 under standardized environmental and procedural conditions to ensure reliability and accuracy. Higher values indicate better skin hydration, while lower values indicate increased dryness.

  4 months (Baseline, Week 8, Week 12, Week 16)

• Transepidermal Water Loss

  measured by tewameter on day 0, then at 8, 12, and 16 weeks.

  4 months

• Facial Skin Elasticity (R2 Parameter Via Cutometer)

  Skin elasticity was assessed using a Cutometer with the R2 parameter (Ua/Uf), which measures gross elasticity. R2 values range from 0 to 1.0, with higher values indicating better skin elasticity. Measurements were collected under standardized conditions at Baseline (Day 0), Week 8, Week 12, and Week 16.

  Baseline, Week 8, Week 12, Week 16

• Facial Skin Wrinkles

  Visioscan measurements were taken at baseline, then at 8, 12, and 16 weeks by using a 4-grade percentage wrinkle improvement scale.

  4 months

• Facial Melanin Index

  Facial pigmentation was assessed using the Mexameter, which measures melanin content via light absorption and reflection. The device reports values on a scale from 0 to 999, where higher values represent greater melanin concentration. Measurements were collected at standardized facial sites at Baseline, Week 8, Week 12, and Week 16. Higher scores indicate worse pigmentation.

  4 months

• Overall Facial Skin Appearance (Photo Evaluation Using SGAIS)

  Facial skin appearance was evaluated using the Subject Global Aesthetic Improvement Scale (SGAIS), a 5-point scale where higher scores indicate greater improvement. Scores were assigned by two board-certified dermatologists who assessed photographs taken by the Visia-CR imaging system at Baseline, Week 8, Week 12, and Week 16. SGAIS scoring definition: 1 = Worse, 2 = Mild improvement (\<25%), 3 = Moderate (25-49%), 4 = Much improved (50-74%), 5 = Very much improved (≥75%).

  4 months

Secondary Outcomes (2)

• Subject Satisfaction in Improving Skin Hydration, Elasticity, Wrinkles, and Pigmentation

  4 months

• Adverse Events

  4 months

Study Arms (1)

Epidermal Growth Factor Serum Application

EXPERIMENTAL

Participants received Epidermal growth factor serum application on the face daily for two months compared to pre and post-results of skin quality.

Drug: Epidermal Growth Factor

Interventions

Epidermal Growth Factor DRUG

Apply facial twice daily.

Also known as: Epidermal Growth Factor Serum

Epidermal Growth Factor Serum Application

Eligibility Criteria

• Age: 40 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Thai
• Mild to moderate facial skin condition, as measured by 1-2 points on the hyperpigmentation status scale or 2-3 points on the wrinkle severity grading scale.

You may not qualify if:

• Use of lotions or skin care products containing ingredients such as vitamin A/C, hydroquinone, or anti-aging agents.
• Sunbathing
• Hypersensitivity to serum components
• Pregnancy and breast-feeding
• Active skin diseases such as eczema or atopic dermatitis at the application site

Sponsors & Collaborators

• Institute of Dermatology, Thailand: lead

Study Sites (1)

Institute of Dermatology

Bangkok, 10400, Thailand

Location

MeSH Terms

Interventions

Epidermal Growth Factor

Intervention Hierarchy (Ancestors)

Gastrointestinal Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; EGF Family of Proteins; Intercellular Signaling Peptides and Proteins; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Biological Factors

Limitations and Caveats

The small sample size should be considered. Further research involving a larger population or control group is recommended for conclusive insights into the efficacy of EGF serum.

Results Point of Contact

• Title: Dr. Supawee Phanmamuang
• Organization: Institute of Dermatology, Thailand

dewsupawee@gmail.com

6623545222

Study Officials

• Chumsaeng Chumsaengsri

  Institute of Dermatology

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident of Dermatology

Study Record Dates

• First Submitted: January 30, 2023
• First Posted: February 13, 2023
• Study Start: January 30, 2023
• Primary Completion: June 5, 2024
• Study Completion: December 12, 2024
• Last Updated: July 31, 2025
• Results First Posted: July 31, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

TH (1)